HARMONY BIOSCIENCES HOLDINGS, INC. Payments to Acquire Debt Securities, Available-for-sale
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Payments to Acquire Debt Securities, Available-for-sale of $331.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $152.53M, a 538.22% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $179.00M, a 835.58% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $18.84M, a 47.21% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $24.28M, a 4.27% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $86.15M, a 18.18% decline from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $105.29M, a 17.40% decline from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $127.47M, a 15.12% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $110.73M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $152.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $331.53M 10-Q · filed 2026-08-04 | $350.37M derived: sum of 3 quarters · filed 2026-08-04 | $374.65M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $179.00M 10-Q · filed 2026-05-07 | $197.83M derived: sum of 2 quarters · filed 2026-05-07 | $222.11M derived: sum of 3 quarters · filed 2026-05-07 | $246.01M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $18.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $43.12M derived: sum of 2 quarters · filed 2026-02-24 | $67.02M derived: sum of 3 quarters · filed 2026-08-04 | $86.15M 10-K · filed 2026-02-24 |
| 2025-09-30 | $24.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $48.18M derived: sum of 2 quarters · filed 2026-08-04 | $67.31M 10-Q · filed 2025-11-04 | $103.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $23.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $43.03M 10-Q · filed 2026-08-04 | $78.72M derived: sum of 3 quarters · filed 2026-08-04 | $102.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $19.13M 10-Q · filed 2026-05-07 | $54.82M derived: sum of 2 quarters · filed 2026-05-07 | $78.10M derived: sum of 3 quarters · filed 2026-05-07 | $99.31M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $35.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $58.97M derived: sum of 2 quarters · filed 2026-02-24 | $80.18M derived: sum of 3 quarters · filed 2026-02-24 | $105.29M 10-K · filed 2026-02-24 |
| 2024-09-30 | $23.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $44.50M derived: sum of 2 quarters · filed 2025-11-04 | $69.60M 10-Q · filed 2025-11-04 | $91.22M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $21.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $46.32M 10-Q · filed 2025-08-05 | $67.93M derived: sum of 3 quarters · filed 2026-02-24 | $100.94M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $25.11M 10-Q · filed 2025-05-06 | $46.72M derived: sum of 2 quarters · filed 2026-02-24 | $79.73M derived: sum of 3 quarters · filed 2026-02-24 | $104.80M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $21.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $54.62M derived: sum of 2 quarters · filed 2026-02-24 | $79.69M derived: sum of 3 quarters · filed 2026-02-24 | $127.47M 10-K · filed 2026-02-24 |
| 2023-09-30 | $33.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $58.08M derived: sum of 2 quarters · filed 2024-10-29 | $105.86M 10-Q · filed 2024-10-29 | $160.95M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $25.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $72.85M 10-Q · filed 2024-08-06 | $127.94M derived: sum of 3 quarters · filed 2025-02-25 | $161.17M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $47.78M 10-Q · filed 2024-04-30 | $102.87M derived: sum of 2 quarters · filed 2025-02-25 | $136.10M derived: sum of 3 quarters · filed 2025-02-25 | |
| 2022-12-31 | $55.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $88.32M derived: sum of 2 quarters · filed 2025-02-25 | $110.73M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $33.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $55.64M 10-Q · filed 2023-10-31 | ||
| 2022-06-30 | $22.41M 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |